在帕金森病中被破坏的副腹腔下丘脑核功能连接与便秘的帕金森病
Xiaorong Hou1, Hongfei Zhou1, Qiugui Zhou1
1Department of Neurology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Neurogastroenterology and motility
|January 21, 2025
概括
帕金森病 (PD) 中的便秘可能源于大脑连接的改变. 具体来说,副腹腔下垂体核 (PVN) 途径的功能连接性减少与早期PD患者的便秘有关.
科学领域:
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
- 神经学 神经学
背景情况:
- 便秘是帕金森病 (PD) 的一个常见的非运动性症状,通常在早期出现.
- 在PD中便秘的确切原因尚未完全理解.
- 之前的研究表明,胃肠道功能障碍与偏心室下丘脑核 (PVN) 中功能连接的改变之间存在联系.
研究的目的:
- 调查PVN在早期PD患者便秘的发展中的作用.
- 为了比较患有便秘和没有便秘的PD患者之间的大脑网络组织.
- 探索PVN功能连接和PD症状严重程度之间的关系.
主要方法:
- 纳入了66名PD患者 (有或没有便秘) 和30名健康对照.
- 所有参与者获得了T1加权和休息状态功能性MRI (fMRI) 扫描.
- 使用基于voxel的形态测量和功能连接分析.
主要成果:
- 与没有便秘的患者相比,患有便秘的PD患者在PVN-pontine tegmentum通路中的功能连接性降低 (p=0.006).
- 两组PD之间没有发现基底腺回路的差异.
- PVN-pontine tegmentum功能连接与UPDRS和NMSS分数负相关.
- 在PD组之间观察到包括下额前环和小脑的功能连接的显著差异.
- 没有检测到灰色物质体积的统计差异.
结论:
- 异常的PVN功能连接性与帕金森病中便秘的机制有关.
- 下额回形和小脑也可能在PD患者的便秘发生中发挥作用.
- 这项研究提供了对PD中便秘的神经生物学基础的见解.
相关概念视频
01:37Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
01:15Parkinson's Disease: Overview
452
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
452
01:24Parkinson's Disease: Treatment
198
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
198
01:17Irritable Bowel Syndrome I: Introduction
243
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
243
01:20Gastrointestinal Motility Disorders
252
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
252
01:21Drugs for Treatment of Constipation-Predominant IBS
131
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
131